


# Washington State Tuberculosis Services and Standards Manual

## Chapter 8: Treatment of Latent TB Infection



DOH 343-240 May 2024



To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email [doh.information@doh.wa.gov](mailto:doh.information@doh.wa.gov).

## **Contact**

Washington State Department of Health TB Program

Phone: 206-418-5500

Fax: 206-364-1060

[tbservices@doh.wa.gov](mailto:tbservices@doh.wa.gov)

## **Acknowledgements**

In addition to the multiple resources and references in the TB Services and Standards Manual chapters, the Washington State TB Program would like to thank the [Curry International TB Center](#) and the [Alaska State TB Program](#); this manual was adapted from these two resources. The TB Program Team was involved in the initial writing and editing of this manual between 2021 and 2023.

## Table of Contents

<b>About the Washington State Tuberculosis Program Manual .....</b>	<b>4</b>
<b>Purpose .....</b>	<b>4</b>
<b>Audience .....</b>	<b>4</b>
<b>Eliminating Stigmatizing Language .....</b>	<b>4</b>
<b>How to Use This Manual .....</b>	<b>5</b>
<b>Icons .....</b>	<b>5</b>
<b>Chapter 8: Treatment of Latent TB Infection .....</b>	<b>7</b>
<b>Introduction.....</b>	<b>7</b>
Purpose .....	7
Policy .....	8
<b>Whom to Treat .....</b>	<b>8</b>
Lifetime, age-related risks of TB disease after primary infection in the pre-chemotherapy era.....	9
Window Period Prophylaxis for Susceptible and Vulnerable Contacts.....	11
Individuals Who Are High Priority for LTBI Treatment.....	12
<i>IGRA Results</i> .....	12
<i>TST Results</i> .....	12
LTBI Re-Treatment .....	13
<b>Treatment Regimens and Dosages.....</b>	<b>14</b>
Regimens.....	14
Administering Meds.....	17
<i>Self-Administered Therapy (SAT) versus Directly Observed Therapy (DOT)</i> .....	17
<b>Adverse Effects of Drugs Used to Treat LTBI.....</b>	<b>18</b>
Possible adverse effects of INH .....	19
Possible Adverse Effects of Rifampin (RIF) and Rifapentine (RPT).....	20
Drug-Drug Interactions.....	21
<b>Patient Monitoring and Education During Treatment .....</b>	<b>22</b>
Clinical Monitoring .....	22
Laboratory Testing .....	22
Patient Education .....	23
Reporting Reactions.....	23
<b>Assessing Patient Adherence .....</b>	<b>24</b>
Prior To Starting Treatment.....	24
Monthly Assessment of Adherence .....	25
Directly Observed Therapy (DOT) .....	25
<b>Completion of Therapy .....</b>	<b>26</b>
LTBI Cascade of Care .....	28
<b>Treatment in Special Situations .....</b>	<b>29</b>
Human Immunodeficiency Virus and LTBI .....	29
<i>Resources</i> .....	29

Pregnancy and Breastfeeding .....	30
<i>LTBI Treatment Regimens for Pregnant Women</i> .....	30
<i>Resources</i> .....	30
Drug Induced Liver Injury (DILI) .....	31
<i>Liver injury and death:</i> .....	31
<i>Alcohol-Use Disorder</i> .....	33
<i>Nonadherence to treatment</i> .....	34
<i>Resources</i> .....	34
<b>Resources .....</b>	<b>35</b>